Welcome to our dedicated page for Livongo Health news (Ticker: LVGO), a resource for investors and traders seeking the latest updates and insights on Livongo Health stock.
Livongo Health (LVGO) provides a technology-driven platform for chronic disease management through connected devices and data analytics. This news hub offers investors and healthcare professionals centralized access to verified updates about the company's strategic direction and market position.
Find timely information on earnings announcements, product innovations, regulatory developments, and partnership agreements. Our curated collection ensures efficient tracking of operational milestones in digital health and telehealth sectors.
Key updates include financial performance reports, technology enhancements to Livongo's health monitoring systems, and collaborations with healthcare providers. All content maintains factual accuracy while avoiding speculative commentary.
Bookmark this page for streamlined access to LVGO's official communications and third-party analyses. Regularly updated to reflect the latest developments in chronic care innovation and corporate strategy.
Livongo Health (Nasdaq: LVGO) has revised its revenue forecast for Q2 2020 to between $86 million to $87 million, surpassing the previous estimate of <$b>73 million to $75 million. The increase includes approximately $2 million to $3 million of non-recurring items. CEO Zane Burke stated that the growth reflects the demand for Livongo's solutions, particularly during the COVID-19 pandemic, which enhances their appeal to major employers and health plans. The company will discuss these results further on a conference call scheduled for August 6, 2020.
Livongo Health announced findings from two studies demonstrating the effectiveness of its remote monitoring technologies in improving care for individuals with diabetes. Presented at the American Diabetes Association’s 80th Scientific Sessions, the first study highlighted predictors of emergency healthcare visits linked to hypo- and hyperglycemic events among 7,633 participants. The second study, involving 1,089 participants in collaboration with Eli Lilly, showed a correlation between platform utilization and improved diabetes management. Livongo's AI+AI engine continues to enhance personalized care by aggregating vital health data.
Livongo has announced the pricing of $475 million in 0.875% convertible senior notes due 2025, increasing from a previous offering of $400 million. The notes, general unsecured obligations, will accrue interest payable semiannually and can be converted into cash or stock. The company expects net proceeds to reach $461.1 million, earmarked for general corporate purposes and capped call transactions. The offering closes on June 4, 2020. Livongo's initial conversion price is set at $75.57 per share, reflecting a 27.5% premium over its June 1, 2020 closing price.
Livongo Health, Inc. (Nasdaq: LVGO) announced a private offering of $400 million in convertible senior notes due 2025, with an option for an additional $60 million. The notes, which will accrue interest and be convertible into cash and shares, aim to support Livongo's corporate purposes, including working capital and business development. Notably, the company plans capped call transactions to mitigate potential stock dilution. The offering is subject to market conditions, with no guarantee on completion. These notes are not registered under the Securities Act, affecting their sale capabilities.
MOUNTAIN VIEW, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc. (Nasdaq: LVGO) announced participation in several upcoming investor conferences. The events include the Jefferies Virtual Healthcare Conference on June 2 at 2:00 p.m. ET, the Stifel 2020 Virtual Cross Sector Insight Conference on June 10 at 10:00 a.m. ET, and the Goldman Sachs 41st Annual Global Healthcare Conference on June 10 at 3:50 p.m. ET. Webcasts of these presentations will be accessible in the Investor Relations section of the company’s website.
Livongo Health, a leader in Applied Health Signals, announced executive presentations at two key investor conferences on May 19, 2020. The conferences include the Needham Virtual Technology & Media Conference at 3:15 p.m. ET and the RBC Capital Markets Global Healthcare Virtual Conference at 4:50 p.m. ET. A live webcast of both presentations will be accessible via the Investor Relations section of Livongo's website. Livongo empowers individuals with chronic conditions, focusing on diabetes, hypertension, and more, through its innovative AI-driven health insights.
Livongo Health reported a remarkable 115% year-over-year revenue growth for Q1 2020, totaling $68.8 million. Membership for Livongo for Diabetes reached over 328,000, a 100% increase year-over-year. The company raised its full-year revenue guidance to $290 million to $303 million. Despite the strong performance, Livongo noted a GAAP net loss of $5.6 million and adjusted EBITDA ranging from ($14 million) to ($10 million) for 2020. The company also announced a partnership with GEHA to provide services for federal employees.
